P
Perceptive Advisors LLC
+ HoldingFRNM
+26.78%
3M Return
$16.310
-0.569 (-3.49%)Al cierre
Loading chart…
- High
- 17.175
- Open
- 16.400
- VWAP
- 16.52
- Vol
- 622.01K
- Mkt Cap
- —
- Low
- 16.060
- Amount
- 10.27M
- EV/EBITDA, TTM
- -0.53
Freenome, Inc. is an early cancer detection company developing blood-based screening tests to identify cancer. The Company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The Company's development of SimpleScreen CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation. SimpleScreen CRC is a colorectal cancer screening test that uses a blood sample to look for signs of cancer and certain precancerous growths. The Company's platform integrates multiomics, artificial intelligence and machine learning to uncover complex biological signals associated with cancer.
AI analysis of FRNM (FRNM)
buyFreenome, Inc. is a good buy right now due to its recent price increase of 7.10% over the last five days and a strong analyst price target of $21, which suggests a potential upside of 42% from the current price of $14.79. Additionally, the company is set to broadly commercialize its cancer screening services, which is expected to drive revenue growth significantly.
Métricas de valoración
The current forward P/E ratio for FRNM (FRNM) is 0.00, compared to its 5-year average forward P/E of .
Whales holding FRNM
Cronología de eventos
Noticias
FRNM FAQ — answered by Alphio AI
Freenome, Inc. is a good buy right now due to its recent price increase of 7.10% over the last five days and a strong analyst price target of $21, which suggests a potential upside of 42% from the current price of $14.79. Additionally, the company is set to broadly commercialize its cancer screening services, which is expected to drive revenue growth significantly.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.